BG106051A - MUTATIONS OF THE ENDOTHELIUM NITROGEN OXIDE SYNTHETASIS, eNOS AND THIEIR APPLICATION FOR GENE THERAPY AND THRAPEUTIC SCREENING - Google Patents
MUTATIONS OF THE ENDOTHELIUM NITROGEN OXIDE SYNTHETASIS, eNOS AND THIEIR APPLICATION FOR GENE THERAPY AND THRAPEUTIC SCREENINGInfo
- Publication number
- BG106051A BG106051A BG106051A BG10605101A BG106051A BG 106051 A BG106051 A BG 106051A BG 106051 A BG106051 A BG 106051A BG 10605101 A BG10605101 A BG 10605101A BG 106051 A BG106051 A BG 106051A
- Authority
- BG
- Bulgaria
- Prior art keywords
- proteins
- screening
- nos
- gene therapy
- enos
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 238000012216 screening Methods 0.000 title abstract 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title 3
- 210000003038 endothelium Anatomy 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108091008611 Protein Kinase B Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000055702 human NOS3 Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
- C12N9/0075—Nitric-oxide synthase (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12955099P | 1999-04-16 | 1999-04-16 | |
| PCT/US2000/009913 WO2000062605A1 (en) | 1999-04-16 | 2000-04-14 | eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG106051A true BG106051A (en) | 2002-06-28 |
Family
ID=22440541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG106051A BG106051A (en) | 1999-04-16 | 2001-10-26 | MUTATIONS OF THE ENDOTHELIUM NITROGEN OXIDE SYNTHETASIS, eNOS AND THIEIR APPLICATION FOR GENE THERAPY AND THRAPEUTIC SCREENING |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US6900038B2 (xx) |
| EP (1) | EP1178722A4 (xx) |
| JP (1) | JP2002541829A (xx) |
| KR (1) | KR100737945B1 (xx) |
| CN (1) | CN100357433C (xx) |
| AU (2) | AU774010B2 (xx) |
| BG (1) | BG106051A (xx) |
| BR (1) | BR0009805A (xx) |
| CA (1) | CA2369764A1 (xx) |
| CZ (1) | CZ20013427A3 (xx) |
| EE (1) | EE200100538A (xx) |
| HK (1) | HK1046081B (xx) |
| HR (1) | HRP20010797A2 (xx) |
| HU (1) | HUP0200799A3 (xx) |
| IL (1) | IL145760A0 (xx) |
| MX (1) | MXPA01010459A (xx) |
| NO (1) | NO20015008L (xx) |
| NZ (1) | NZ514305A (xx) |
| PL (1) | PL351087A1 (xx) |
| RU (1) | RU2257226C2 (xx) |
| SK (1) | SK14692001A3 (xx) |
| UA (1) | UA76939C2 (xx) |
| WO (1) | WO2000062605A1 (xx) |
| YU (1) | YU73301A (xx) |
| ZA (1) | ZA200108463B (xx) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ514305A (en) * | 1999-04-16 | 2004-01-30 | Univ Yale | eNOS mutations useful for gene therapy and therapeutic screening |
| EP1539940A4 (en) | 2002-06-14 | 2006-02-22 | Wisconsin Alumni Res Found | Ribonuclease zymogen CONSTRUCTION |
| MXPA05001906A (es) * | 2002-08-16 | 2005-04-28 | Schering Ag | Mutantes de enos utiles para genoterapia. |
| US20040120930A1 (en) * | 2002-08-16 | 2004-06-24 | Schering Aktiengesellschaft | Gene therapy for critical limb ischemia with wild type or mutant eNOS |
| GB0226463D0 (en) * | 2002-11-13 | 2002-12-18 | Isis Innovation | Mimicking the athletic heart |
| CN1717254A (zh) * | 2002-12-02 | 2006-01-04 | 安增子摩祺株式会社 | 用于治疗或预防血管生成－依赖性症状的组合物 |
| WO2006023879A1 (en) * | 2004-08-20 | 2006-03-02 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
| US7740849B2 (en) * | 2004-09-24 | 2010-06-22 | Beth Israel Deaconess Medical Center | Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders |
| MX2007003522A (es) * | 2004-09-24 | 2007-06-11 | Beth Israel Hospital | Complicaciones del embarazo. |
| MX2008015197A (es) * | 2006-05-31 | 2009-06-23 | Beth Israel Hospital | Metodos de diagnosticar y tratar las complicaciones del embrazo. |
| US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
| CN102159948B (zh) | 2008-07-22 | 2014-06-25 | 普罗美加公司 | 基于adp检测的发光磷酸转移酶或atp水解酶测定 |
| KR20110101142A (ko) * | 2008-12-04 | 2011-09-15 | 사노피 | 헴 결합 단백질 1을 포함하는 방법 및 용도 |
| RU2526575C2 (ru) * | 2012-11-02 | 2014-08-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ повышения иммуносупрессивных свойств мезенхимальных стромальных клеток жировой ткани |
| US9677117B2 (en) | 2014-10-08 | 2017-06-13 | Promega Corporation | Bioluminescent succinate detection assay |
| CN107802826B (zh) * | 2017-10-26 | 2020-02-18 | 首都医科大学宣武医院 | eNOS突变体在促进血管生成中的应用 |
| CN116790603B (zh) * | 2023-08-18 | 2023-10-31 | 成都中科奥格生物科技有限公司 | 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5498539A (en) * | 1992-07-02 | 1996-03-12 | Daiichi Pharmaceutical Co., Ltd. | Bovine endothelial nitric oxide synthase nucleic acids |
| US5658565A (en) * | 1994-06-24 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inducible nitric oxide synthase gene for treatment of disease |
| DE4411402A1 (de) * | 1994-03-31 | 1995-10-05 | Juergen Schrader | DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen |
| FR2722507B1 (fr) * | 1994-07-12 | 1996-08-14 | Rhone Poulenc Rorer Sa | Adenovirus comportant un gene codant pour une no synthase |
| US5968983A (en) * | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
| US5837534A (en) * | 1995-11-14 | 1998-11-17 | The Board Of Regents Of The University Of Texas System | Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells |
| CA2335391A1 (en) * | 1998-10-02 | 2000-04-13 | Kenneth Walsh | Akt compositions for enhancing survival of cells |
| ES2310515T3 (es) * | 1999-03-19 | 2009-01-16 | Aventis Pharmaceuticals Inc. | Acidos nucleicos akt-3, polipeptidos y usos de los mismos. |
| NZ514305A (en) * | 1999-04-16 | 2004-01-30 | Univ Yale | eNOS mutations useful for gene therapy and therapeutic screening |
| JP2003530818A (ja) * | 1999-06-11 | 2003-10-21 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | セリン／トレオニンプロテインキナーゼＡｋｔによる血管内皮成長因子（ＶＥＧＦ）の導入 |
-
2000
- 2000-04-14 NZ NZ514305A patent/NZ514305A/xx unknown
- 2000-04-14 MX MXPA01010459A patent/MXPA01010459A/es not_active Application Discontinuation
- 2000-04-14 WO PCT/US2000/009913 patent/WO2000062605A1/en active Application Filing
- 2000-04-14 KR KR1020017013218A patent/KR100737945B1/ko not_active IP Right Cessation
- 2000-04-14 CN CNB008063257A patent/CN100357433C/zh not_active Expired - Fee Related
- 2000-04-14 EE EEP200100538A patent/EE200100538A/xx unknown
- 2000-04-14 SK SK1469-2001A patent/SK14692001A3/sk not_active Application Discontinuation
- 2000-04-14 IL IL14576000A patent/IL145760A0/xx unknown
- 2000-04-14 UA UA2001107249A patent/UA76939C2/uk unknown
- 2000-04-14 PL PL00351087A patent/PL351087A1/xx not_active Application Discontinuation
- 2000-04-14 CA CA002369764A patent/CA2369764A1/en not_active Abandoned
- 2000-04-14 RU RU2001130901/15A patent/RU2257226C2/ru not_active IP Right Cessation
- 2000-04-14 YU YU73301A patent/YU73301A/sh unknown
- 2000-04-14 CZ CZ20013427A patent/CZ20013427A3/cs unknown
- 2000-04-14 AU AU42378/00A patent/AU774010B2/en not_active Ceased
- 2000-04-14 BR BR0009805-1A patent/BR0009805A/pt not_active IP Right Cessation
- 2000-04-14 JP JP2000611751A patent/JP2002541829A/ja active Pending
- 2000-04-14 HU HU0200799A patent/HUP0200799A3/hu unknown
- 2000-04-14 EP EP00922148A patent/EP1178722A4/en not_active Withdrawn
-
2001
- 2001-09-20 US US09/956,699 patent/US6900038B2/en not_active Expired - Lifetime
- 2001-10-15 ZA ZA200108463A patent/ZA200108463B/en unknown
- 2001-10-15 NO NO20015008A patent/NO20015008L/no not_active Application Discontinuation
- 2001-10-26 BG BG106051A patent/BG106051A/xx unknown
- 2001-10-29 HR HR20010797A patent/HRP20010797A2/hr not_active Application Discontinuation
-
2002
- 2002-10-28 HK HK02107786.1A patent/HK1046081B/zh not_active IP Right Cessation
-
2004
- 2004-07-12 US US10/889,121 patent/US20040253685A1/en not_active Abandoned
- 2004-09-10 AU AU2004210533A patent/AU2004210533A1/en not_active Abandoned
-
2008
- 2008-12-09 US US12/316,128 patent/US7888089B2/en not_active Expired - Fee Related
-
2011
- 2011-02-14 US US13/026,973 patent/US20110173711A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG106051A (en) | MUTATIONS OF THE ENDOTHELIUM NITROGEN OXIDE SYNTHETASIS, eNOS AND THIEIR APPLICATION FOR GENE THERAPY AND THRAPEUTIC SCREENING | |
| PT910647E (pt) | Variantes hiperactivas da dnase i humana | |
| NZ279963A (en) | Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946 | |
| WO1998030694A3 (en) | TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b) | |
| WO2001036640A3 (en) | Human fgf-21 gene and gene expression products | |
| WO1998049300A3 (en) | Truncated vegf-related proteins | |
| ATE362766T1 (de) | Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen | |
| PL1641483T3 (pl) | Białka fuzyjne | |
| ATE342967T1 (de) | Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung | |
| ATE437648T1 (de) | Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen | |
| ATE191922T1 (de) | Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen | |
| AU6847298A (en) | Transcription factor islet-brain 1 (ib1) | |
| WO2004074486A3 (en) | Fusion proteins of interferon alpha muteins with improved properties | |
| AP2000001999A0 (en) | Gene therapy method. | |
| ATE402995T1 (de) | Akt-3 nukleinsäure, polypeptide und deren verwendung | |
| WO2004005475A3 (en) | Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same | |
| WO2000065028A3 (en) | TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR | |
| WO2000001802A3 (en) | Peptide antagonists of the human urokinase receptor and method for selecting them | |
| WO2004005341A3 (en) | Full-length interferon gamma polypeptide variants | |
| WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
| WO1998054209A3 (en) | Human mast cell function-associated antigen (mafa) and uses thereof | |
| WO2002101076A3 (en) | Methods for targeted expression of therapeutic nucleic acid | |
| UA66749C2 (en) | Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases | |
| DE69113049D1 (de) | Varianten des gewebeplasminogenaktivators mit vermindertem abbau. | |
| WO2002068687A3 (en) | Function and application of tob gene in central nervous system of mammal |